iBio Discovers Novel Antibody Targeting Activin E in Collaboration with AstralBio
Achievement strengthens iBio’s partnered cardiometabolic and obesity program while showcasing its proprietary AI-driven drug ...
FierceBiotech5d
iBio pens $29M biobucks deal with AstralBio for obesity med designed to preserve muscle mass
San Diego-based iBio has signed a backloaded agreement with its existing partner AstralBio for a preclinical anti-myostatin ...
iBio, Inc.: iBio Discovers Novel Antibody Targeting Activin E in Collaboration with AstralBio
SAN DIEGO, Jan. 07, 2025 (GLOBE NEWSWIRE) -- iBio, Inc. (NYSEA: IBIO), an AI-driven innovator of precision antibody immunotherapies, in collaboration with AstralBio Inc., announced today the developme ...
manilatimes6d
iBio Expands Cardiometabolic and Obesity Program with Anti-Myostatin Antibody Discovered Using its Proprietary Platform, In-Licensed from AstralBio
Building on the success of the anti-Myostatin program, iBio Launches New Program Featuring Myostatin + Activin A Bispecific ...
Nano-Cap iBio Expands Obesity Program With New Antibody Using In-Licensed Platform
On Thursday, iBio, Inc. (NYSE:IBIO) expanded its cardiometabolic and obesity treatment development program by in-licensing a ...
Nasdaq6d
iBio, Inc. Expands Obesity Treatment Pipeline with In-Licensing of Long-Acting Anti-Myostatin Antibody IBIO-600 from AstralBio, Inc.
The upfront payment of $750,000 in common stock to AstralBio may dilute existing shareholders' equity. iBio is solely responsible for the development and commercialization of IBIO-600, placing ...
Business Insider6d
iBio Expands Cardiometabolic and Obesity Program with Anti-Myostatin Antibody Discovered Using its Proprietary Platform, In-Licensed from AstralBio
Pursuant to the agreement, AstralBio will receive an upfront payment of $750,000, which iBio has paid by issuing its common stock to AstralBio. In addition, AstralBio will be eligible for ...
iBio expands cardiometabolic, obesity treatment development program
Bio (IBIO) announced the expansion of its cardiometabolic and obesity treatment development program by in-licensing a potentially ...
ETF Daily News6d
iBio Enters Exclusive License Agreement with AstralBio for Development of Anti-Myostatin Antibody
In consideration for these rights, iBio has agreed to pay AstralBio an upfront license fee of $750,000, to be paid in shares of iBio’s common stock. Additionally, milestone payments of up to $28 ...